When did the Indivior (INDV) CFO’s share sale take place?

The CFO’s sale took place on June 8, 2026. On that date, Ryan Preblick executed an open-market sale of 36,000 Indivior Common Stock shares at $37.70 per share, as disclosed in the Form 4 insider trading report.

What price did the Indivior (INDV) CFO receive per share in the sale?

The CFO’s open-market sale was executed at $37.70 per share. This price applies to the 36,000 shares of Indivior Common Stock sold on June 8, 2026, as disclosed in the insider trading Form 4 filing.

Indivior (INDV) CFO sells 36,000 shares under Rule 10b5-1 plan, retains 284,751

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. reported that Chief Financial Officer Ryan Preblick sold 36,000 shares of Common Stock in an open-market transaction at $37.70 per share on June 8, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026. Following this transaction, Preblick directly holds 284,751 shares, indicating he retains a substantial equity stake in the company.

Insider Trade Summary 10b5-1

Net Seller: 36,000 shares ($1,357,200)

Net Sell 1 txn

Insider Preblick Ryan

Role Chief Financial Officer

Sold 36,000 shs ($1.36M)

Type	Security	Shares	Price	Value
Sale	Common Stock	36,000	$37.70	$1.36M

Holdings After Transaction: Common Stock — 284,751 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 36,000 shares Sale price: $37.70 per share Shares held after sale: 284,751 shares +2 more

5 metrics

Shares sold 36,000 shares Open-market sale on June 8, 2026

Sale price $37.70 per share Price for Common Stock sale

Shares held after sale 284,751 shares Direct holdings following transaction

Form type Form 4 Insider transaction report

Trading plan adoption date March 6, 2026 Rule 10b5-1 plan for the sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/10/2026 - 06:04 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Preblick Ryan

(Last)

(First)

(Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD

VIRGINIA

23235

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/08/2026		S⁽¹⁾		36,000	D	$37.7	284,751	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

Remarks:

	/s/Alice Givens, Power of Attorney	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Indivior (INDV) report for its CFO?

Indivior reported that CFO Ryan Preblick sold 36,000 shares of Common Stock. The open-market sale occurred at $37.70 per share and was made under a Rule 10b5-1 trading plan, which pre-schedules trades to avoid timing concerns.

How many Indivior (INDV) shares does the CFO hold after the sale?

After the reported transaction, CFO Ryan Preblick directly holds 284,751 shares of Indivior Common Stock. This post-transaction balance shows that, despite the sale, he continues to maintain a significant personal ownership position in the company’s equity.

Was the Indivior (INDV) CFO trade made under a Rule 10b5-1 plan?

Yes. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan adopted on March 6, 2026. Such plans pre-arrange trades, helping separate routine portfolio management from discretionary market-timed transactions.